G20
Conditions
Interventions
Group 1: healthy individuals without Glucocerebrosidase (GBA) mutations: clinical-neurological examination, UPDRS III+IV, BDI-II, NPI-Q, MoCA, TMT, UMSARS 9-12, NMS-Q, Compass31, olfactory performance
Sponsors
DZNE
Eligibility
Sex/Gender
All
Age
40 Years to 90 Years
Inclusion criteria
Inclusion criteria: - Ability and willingness to communicate comprehensible with the study physician, as well as to understand the demands of the study and to comply with them. - Sign a written consent form for the participation in the study. - Understanding, that a withdrawal of the study participation is possible at any time without negative effects concerning continuation of medical treatment. - manifesting Parkinson disease according to UKBB criteria or no manifesting Parkinson disease according to UKBB criteria.
Exclusion criteria
Exclusion criteria: - Any restriction that hinder the patient to give his consent or comply with any demands of the study. - Other neurodegenerative diseases that make it impossible for the patient to communicate in an adequate way with the study physician or comply with the demands of the study or understand them. - Manifesting dementia according to ICD10. - Occurred cerebral ischemia or cerebral bleeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Identification and analysis of factors that cause the disease in GBA carriers or prevent it. - Identiciation of individuals that will develop Parkinson disease because of GBA mutations in the earliest possible stage and examination of these early stages. - Improvement of the knowledge about similarities and differences between Parkinson patients with and without GBA mutation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Identification of specific biomarkers in blood, CSF and cell models | — |
Countries
Germany
Contacts
Public ContactNicole Vollmer
DZNE
Outcome results
None listed